Greetings, and welcome to Oncternal Therapeutics' Third Quarter 2023 Financial Results Conference Call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Richard Vincent, Chief Financial Officer. Please go ahead. Thank you, Rob. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our President and CEO, Dr. James Breitmeyer, and our CMO, Dr. Salim Yazji. Today's call includes a business update and discussion of our third quarter ended September 30, 2023 financial results that were filed earlier today. Today's press release and a replay of today's call will be available on the investor relations section of Oncternal's website for at least the next 30 days. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events, such as our business and product development strategies, the timing of initiation of our preclinical and clinical studies, the timing of planned interim data updates, the timing of our regulatory filings and our cash runway. Our actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business. These forward-looking statements should be considered in conjunction with and are qualified by the cautionary statements contained in today's press release and our SEC filings, including our Form 10-Q filed today and our previously filed Form 10-K for the full year ended December 31, 2022. This call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 9th, 2023. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this call. With that, it is my pleasure to hand the call over to our CEO, Dr. Jim Breitmeyer. Thank you, Rich, and good afternoon, everyone. At Oncternal, we are now advancing two first-in-class clinical programs targeting cancers for patients with significant unmet medical needs. In October 2023, we dosed our first patient in our phase 1/2 dose escalation study of ONCT-534, our novel dual-action androgen receptor. Hello? Hello. Yeah, you're back. Okay. Thank you. I apologize, everybody. I'm calling in internationally. ONCT-534 is for patients with metastatic castration-resistant prostate cancer who have progressed after treatment with approved AR pathway inhibitors. In October, we also received Fast Track designation from FDA, further supporting our belief that ONCT-534 may be an important therapeutic alternative for patients with advanced prostate cancer. We expect our initial clinical data readout in the first half of 2024. With respect to ONCT-808, our ROR1 targeting autologous CAR T program, we continue to execute on enrollment of the phase 1/2 study in aggressive B-cell non-Hodgkin's lymphoma patients. We've now dosed the first few patients and plan to announce initial clinical data in December of this year, with additional clinical readouts in 2024. The manufacturing process is delivering large numbers of high-quality CAR-expressing T-cells and may offer reduced vein-to-vein times. Overall, we are delivering on our plan to advance our two clinical programs, ONCT-534 and ONCT-808, through potential significant value inflection points by the first half of 2024, all while maintaining our cash runway guidance into 2025. With that, I'd like to now turn the call to Oncternal CMO, Salim Yazji, to expand on our clinical progress with ONCT-534 and ONCT-808. Salim? Thank you, Jim. As Jim mentioned, we are excited to have dosed, to have dosed our first patients in the study of ONCT-534-101, a phase 1/2 dose-escalation study that's enrolling patients with metastatic castration-resistant prostate cancer, with progressive disease that have relapsed or are refractory to prior androgen receptor pathway inhibitors, such as enzalutamide or abiraterone. Based on preclinical studies and its novel mechanism of action, we believe that ONCT-534 can provide an important treatment alternative to these patients by addressing a key tumor escape mechanism that results in resistance to currently available AR pathway inhibitors, including AR mutation, AR amplification, and splice variants such as AR-V7. Enrollment is advancing according to plan, and we continue to expect to report initial data in the first half of 2024. In September, we announced the establishment of our Prostate Cancer Scientific Advisory Board, which includes distinguished academic and industry leaders in the prostate cancer field, such as Professor Johann de Bono from the ICR in London, Dr. Matthew Smith from Mass General, and Dr. Evan Yu from the Fred Hutch. We look forward to working with our SAB to develop our future clinical and registrational strategy for ONCT-534. With respect to ONCT-808, our autologous ROR1 targeting CAR T, we continue to dose patients in the dose escalation portion of our study. ONCT-808-101, a phase 1/2 study for patients with relapsed or refractory progressive, aggressive B-cell lymphoma, including those who have failed previous CD19 CAR T therapy. We have seen encouraging expansion and persistence of CAR-expressing T-cells in the study, which has been demonstrated to be positively correlated with clinical response in previous CD19 CAR T studies. With this, I now turn the call to our CFO, Rich Vincent. Rich? Thank you, Salim. Our revenue is currently derived from research and development grants received from the NIH. Our grant revenue was $0.2 million for the third quarter ended September 30, 2023. Our total operating expenses for the third quarter were $10.6 million, including $1.7 million in non-cash stock-based compensation expense. Research and development expenses totaled seven point five million, and general and administrative expenses totaled $3.1 million. Interest income for the quarter was $0.5 million. Net loss for the third quarter was $9.9 million, for a loss of seventeen cents per share, basic and diluted. As of September 30, 2023, we had 59 million shares of common stock outstanding, $40.3 million in cash and investments, and no debt. We believe these funds will be sufficient to fund our operations into 2025. With respect to upcoming milestones, we remain on track. For ONCT-808, our ROR1 autologous CAR T, we expect to report initial clinical data in December 2023, with additional data readouts in 2024. For ONCT-534, our lead DAARI product candidate, we expect to present initial clinical data in the first half of 2024. Now, I will turn the call back over to Jim. Jim? Thank you, Rich. We are very pleased with the recent progress in our two clinical programs, while reiterating our cash runway guidance into 2025. We are excited to be advancing the clinical development of novel pathways in areas with very high unmet medical need, such as CD19 relapses in aggressive lymphoma and metastatic castrate-resistant prostate cancer, harboring AR mutations and splice variants. Thank you for joining us today, and we look forward to updating you during upcoming medical and banking conferences. With that, I will turn things back to Rob for the Q&A portion of this afternoon's call. Thank you. At this time, we'll be conducting a question-and-answer session. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question is from Carl Byrnes with Northland Capital Markets. Please proceed with your question. Thanks for the questions, and also congratulations on your progress. I'm wondering if you can provide a little more detail with respect to the velocity of patient recruitment in the ONCT-534 dose escalation study, and this is obviously considering the urgent unmet medical need of indication. And then I have a follow-up. Go ahead, Salim. Yeah. So, you know, as you know, we designed the study based on the BOIN design, which should allow us to move forward with the first two cohorts, with only one patient each, if there is no toxicity or side effects during those cohorts. So far, I mean, you know, I think the enrollments and everything is going as expected. And Carl, there are a lot of these patients out there. Yeah, and that, that's where I was going. Is this... It seems like, you know, these trials, as you progress in advance, they should be relatively easy, you know, to populate and enroll. We hope so. You know, you never know, but what we're finding is that our, for both studies, the investigators are enthusiastic, and the number of patients who are in their systems with these kinds of unmet need, seem to be ample for a good enrollment pattern. Excellent. Then just shifting gears a little bit on 808, do you have any thoughts there in terms of the potential efficacy signal with the data readout in December, considering the dose level being relatively close to recommended phase II doses of other CAR T therapies? Thanks. Yeah, I'll take that one, Salim. I think that, as you probably know, with aggressive lymphoma, CAR T, responses to CAR T have some- ... pretty quickly. And, you know, from the 19 CAR T, the median time to response was 1-2 months. So if there's any, you know, similarity between this CAR T and response and so what? You're cutting out. I'm sorry, Jim, I think you broke up a bit. Yeah, I did. I'm sorry. Can you, can you hear me better now? Yes. Yes. Okay. I just switched phones. So, given that other CAR T programs have shown that complete responses can develop quickly, we're optimistic that we may have some efficacy to talk about in December. Great. Great. Again, congrats. Congratulations on the progress. Our next question comes from Hartaj Singh with Oppenheimer and Company. Please proceed with your question. Great, thank you. Thanks for the couple of questions and really nice update. Things are moving along pretty quickly, Jim and Salim and team. I guess on 808, just one question there is following up on the previous questions. You know, what would you like to see, you know, whether it's dose level 1, 2, or 3, you know, a minimum amount of efficacy, in order to move forward? And then, you know, when you do move forward, you're thinking about dose expansion, what are you thinking in terms of what would be an acceptable durability that you'd like to, like, you know, you'd like to see as you sort of follow these patients onwards? And then, you know, on the other program with ONCT-534, again, you know, just similar questions. You're gonna have a lot of data being presented there, you know, early stage. What should we be looking for, you know, that signals to us that you're getting close to a sort of a, you know, moving to dose expansion from the dose escalation part of the study? Thank you. Jim, do you want me take this one? Okay, so Hartaj, I can start actually, while Jim probably establishing the connection. You know, as you know, we really dealing with very sick patients, especially patients who are often relapsed from prior CD19 CAR T. Unfortunately, I mean, you know, these patients the progression-free survival and overall survival is very short, which is usually in months, not even in years. And what we would expect, we would expect to see some objective response and also durability of response. And that's a big question here. What will be good as a durable response in those patient populations that already failed prior CAR T? I think it's a very objective question, and we need to, you know, still see some of that data and evaluate it. Because usually median progression-free survival there is no more than three months currently, and then the survival rate is no more than six months. So I think we are really dealing with very aggressive and very sick patients, but we hoping for the best. So I'll stop here and I'll take any questions if there's any additional ones from you, Hartaj. No, no, Salim, that's really good. And then just on 534, you know, how do we-- What, how, I guess, what do you expect to see? I mean, you've got all the way you can go to 600 milligram oral daily, right? It seems like, and, but, you know, when, where do you think you could get to before you would expect DLT? Would you need to go all the way to 600? Do you think it could be before that? And back to the question. I think it is also, you know, it's all depends, I mean, you know, on the dose escalation and how fast we can go there. But we will actually believe that a therapeutic dose or the efficacy dose maybe start from 300 above, and which is that would be the fourth cohort. We may start seeing things earlier than that, and you know, we're hoping to do that. But I think it's time, time will actually be on our side to see if we'll be able to see any early responses in earlier cohorts. Let me, let me add something. Yes, Jim, go ahead. Yeah. Yeah, yeah. So, there was a very interesting panel discussion at the SITC conference last week, where several members of the FDA addressed Project Optimus. And what they made clear and emphasizing what's in the FDA guidance here, is that FDA is looking for developers to establish a balance between efficacy and safety. And they are not, they're in oncology in particular, they're encouraging early development to learn more than just the maximum tolerated dose, and to explore doses below MTD to look for that perfect balance between efficacy and safety. And so this was, what was particularly helpful about this panel, was that it was being discussed in the context of cell therapy, such as 808. ...But the same principles will apply to the choice of dose for ONCT-534 as well. Yeah. And, Jim, you know, I guess, I was just thinking, you, I know you've probably mentioned this, this before. Just remind us again, why do you have two dose levels, dose level A and dose level B, when you move forward from the dose escalation part of the study? That it's exactly for that reason, Hartaj. It's what FDA is looking for in this Project Optimus. And they make clear that whenever possible, they expect to see randomization between the two dose levels, so that by the before you start a registration intent study, FDA will have the opportunity to examine efficacy and safety and risk-benefit ratio for more than one dose. Yeah. No, this is all very helpful. Thank you for, for the question. Thank you. Our next question comes from Kemp Dolliver with Brookline Capital Markets. Please proceed with your question. Great, thank you. So the question relates to 534. And, you know, Novartis recently presented the data from PSMAfore, which, as you know, is the pre-taxane setting, and, you know, we're expecting data any day now from the SPLASH trial, which is also in that same patient population. And, I mean, based on what you've seen so far and the commentary regarding how, you know, these drugs would be used in that setting, how are you thinking about the opportunity for 534? Yeah, good question, Kemp. So the challenge from the PSMAfore study is that there is a slightly worse overall survival in the active treatment group, in the intent to treat analysis. And so we know that FDA will be looking at their safety data in a very close manner. And what we believe is that there is still a very high desire for both the patients with prostate cancer and their physicians to have another treatment option available, an oral treatment option available, that doesn't require referral to a different specialist to treat after resistance to enzalutamide or abiraterone develop. So we're remaining confident that we have a commercially viable and clinically important indication here in the prostate cancer continuum. Got it. Thank you. We have reached the end of the question and answer session. I would now like to turn the call back over to Dr. James Breitmeyer for closing comments. Thank you, Rob. We appreciate everybody's time and attention and the good questions this afternoon. We are looking forward to an exciting end of this year and first half of next year, and look forward to staying in touch with you. So with that, thank you for your time, and we will sign off. This concludes today's conference. You may disconnect your lines at this time, and we thank you for your participation.